510(k) Report

510(k) · Cleared

Cleared

Alinity m Resp-4-Plex

K241573510(k) TraditionalCleared Feb 14, 2025256-day reviewClass II21 CFR 866.3981

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Molecular, Inc. · QOF Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents

Cleared on Feb 14, 2025 as substantially equivalent to K222736 (Hologic, Inc., 2023) after a 256-day review. Its family tree reaches back 2 generations to 2021.

Decided
Feb 14, 2025
Review
256 days
Class
Class II
Product code
QOF
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN200031 (2021). No later device cites it as a predicate yet.

  1. Root · 2 generations backDEN200031 BioFire Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics, LLC · 2021
  2. 1 generation backK222736 Panther Fusion SARS-CoV-2/Flu A/B/RSV AssayHologic, Inc. · 2023 · Recalled
  3. This deviceK241573 Alinity m Resp-4-PlexAbbott Molecular, Inc. · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN200031BioFire Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics, LLC2021—
−1K222736Panther Fusion SARS-CoV-2/Flu A/B/RSV AssayHologic, Inc.20231
0 (this device)K241573Alinity m Resp-4-PlexAbbott Molecular, Inc.2025—
FIG. 1 — Lineage of K241573, 2021–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QOF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QOF device

  1. #1 K241240 Panther Fusion SARS-CoV-2/Flu A/B/RSV Assayscore 17.0 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K222736Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
Summary page 7
…Predicate Device 510(k) Date Cleared Hologic™ Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay K222736 May 16, 2023 Alinity m Resp-4-Plex February 2025…
Hologic, Inc.20231

Also cleared against K222736: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 3 companies; a new generation was cleared every 2.2 years on median.
  • 1 of the 2 ancestors has a recall of any class.
  • 1 other device also cites its predicate K222736.

How does its category compare?

All QOF devices

QOF Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QOF

13in 2025

2021: 12023: 72024: 92025: 132026 (partial year): 8
2007high 13 (2025) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QOF

178in 2025

2023: 238 days median2024: 147 days median2025: 178 days median2026 (partial year): 128 days median
2007high 238 (2023) · low 147 (2024)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QOF

2so far in 2026, the most since 2007

2023: 12024: 12025: 12026 (partial year): 2
2007high 2 (2026) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · QOF

10in 2025

2023: 62024: 302025: 10
2007high 30 (2024) · low 0 (2007)2025

MAUDE reports naming product code QOF, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20211—00
20220—00
2023723816
20249147130
202513178110
202681282—

What is it indicated for?

Alinity m Resp-4-Plex is a multiplexed real-time in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for use with the automated Alinity m System for the qualitative detection and differentiation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza A virus, influenza B virus and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens collected from patients with signs and symptoms of respiratory tract…

Read the full statement (238 words)

Alinity m Resp-4-Plex is a multiplexed real-time in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for use with the automated Alinity m System for the qualitative detection and differentiation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), influenza A virus, influenza B virus and Respiratory Syncytial Virus (RSV) in nasopharyngeal swab specimens collected from patients with signs and symptoms of respiratory tract infection. Clinical signs and symptoms of respiratory tract infection due to SARS-CoV-2, influenza A, influenza B, and RSV can be similar.

The Alinity m Resp-4-Plex assay is intended for use in the differential detection of SARS-CoV-2, influenza A, influenza B and/or RSV RNA and aids in the diagnosis of COVID-19, influenza and/or RSV infections if used in conjunction with other clinical and epidemiological information, and laboratory findings. SARS-CoV-2, influenza A, influenza B and RSV viral RNA are generally detectable in nasopharyngeal swab specimens during the acute phase of infection. This test is not intended to detect influenza C virus infections.

Positive results are indication of the presence of the identified virus, but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. The agent(s) detected by the Alinity m Resp-4-Plex assay may not be the definite cause of disease.

Negative results do not preclude SARS-CoV-2, influenza A, influenza B and/or RSV infections and should not be used as the sole basis for diagnosis, treatment or other patient management decisions.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K241573: Alinity m Resp-4-Plex.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K241573

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026